Showing 221 - 235 results of 235 for search '"Food and Drug Administration"', query time: 0.10s Refine Results
  1. 221
  2. 222
  3. 223

    Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity by Andrew Overholser, Eric Czech, Linda Speer, Joel Wilson, Alex Overholser

    Published 2025-02-01
    “…The current United States Food and Drug Administration (FDA) approved pharmaceutical therapy choices for long-term use include a combination of phentermine-topiramate, combination bupropion-naltrexone, orlistat, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dual action GLP-1RAs and gastric inhibitory peptide agonists (GIP). …”
    Get full text
    Article
  4. 224
  5. 225

    Development and characterization of orthotopic patient-derived xenograft models of peritoneal metastatic mucinous appendiceal adenocarcinoma by I. Ito, V.K. Pattalachinti, A.M.G. Yousef, S. Chowdhury, M.M. Fanaeian, E. Haque, B.B. Gunes, M. Yousef, E.R. Salle, M.A. Zeineddine, S. Ji, R. Li, W. Wang, B.A. Helmink, M.W. Taggart, M.G. White, K.F. Fournier, N.W. Fowlkes, J.P. Shen

    Published 2025-03-01
    “…The lack of preclinical models of AA has hindered drug development and is a major factor in why AA remains without a single Food and Drug Administration-approved systemic treatment. Materials and methods: Tumors from 16 patients with appendiceal neoplasms (15 AAs and 1 high-grade appendiceal neoplasm) were implanted into the flank and the peritoneal cavity of immunodeficient mice leading to the successful establishment of three AAPDX models. …”
    Get full text
    Article
  6. 226

    Potentially commercializable nerve guidance conduits for peripheral nerve injury: Past, present, and future by Chundi Liu, Mouyuan Sun, Lining Lin, Yaxian Luo, Lianjie Peng, Jingyu Zhang, Tao Qiu, Zhichao Liu, Jun Yin, Mengfei Yu

    Published 2025-04-01
    “…To enhance comprehension of clinical situations, this article provides a comprehensive analysis of the clinical efficacy of nerve conduits approved by the United States Food and Drug Administration. It proposes that the initial six months post-transplantation is a critical window period for evaluating their efficacy. …”
    Get full text
    Article
  7. 227
  8. 228

    Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types by Vivek Subbiah, Samuel J Klempner, Neeraj Agarwal, David P Carbone, Amit Mahipal, Shilpa Gupta, David Fabrizio, Jeffrey S Ross, Gerald Li, David R Gandara, Miles C Andrews, Jonathan W Riess, Ramez N Eskander, Ryon P Graf, Geoffrey R Oxnard, Sarah Sammons, Jeremy Snider, Lilia Bouzit, Cheryl Cho-Phan, Megan Price, Julia C F Quintanilha, Richard Sheng Poe Huang

    Published 2025-02-01
    “…The KEYNOTE 158 trial supported United States Food and Drug Administration (FDA) approval of the Foundation Medicine test (FoundationOneCDx) at TMB≥10 mut/Mb as a companion diagnostic (CDx) for single-agent pembrolizumab in second+line. …”
    Get full text
    Article
  9. 229
  10. 230

    Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta... by Leiling Liu, Zhiqi Li, Wenrui Ye, Pu Peng, Yurong Wang, Luqing Wan, Jiangnan Li, Mei Zhang, Yihua Wang, Runqi Liu, Danyan Xu, Jingjing Zhang

    Published 2025-01-01
    “…Randomised controlled trials evaluating weight-loss pharmacotherapies approved by the Food and Drug Administration (FDA) or European Medicines Agency (EMA) for treating overweight or obesity were included. …”
    Get full text
    Article
  11. 231

    The American Society of Pain and Neuroscience (ASPN) Guidelines and Consensus on the Definition, Current Evidence, Clinical Use and Future Applications for Physiologic Closed-Loop... by Pope JE, Deer TR, Sayed D, Antony AB, Bhandal HS, Calodney AK, Chakravarthy K, Costandi S, Diep J, Durbhakula S, Fishman MA, Gilligan C, Goree JH, Guirguis M, Hagedorn JM, Hunter CW, Kallewaard JW, Kapural L, Lam CM, Li S, Mayrsohn B, Nijhuis H, Nikolic S, Petersen EA, Poree LR, Puri SK, Reece DE, Rosen SM, Russo MA, Shah JM, Staats PS, Verrills P, Vu CM, Levy RM, Mekhail N

    Published 2025-02-01
    “…Recently, the Food and Drug Administration (FDA) released a guidance on physiologic closed loop controlled (PCLC) devices, highlighting the potential for these therapies to deliver accurate, consistent, real-time therapy, enhancing medical care and reducing variability. …”
    Get full text
    Article
  12. 232
  13. 233

    Contextual Vulnerability Should Guide Fair Subject Selection in Xenotransplantation Clinical Trials by Gianna Strand

    Published 2023-03-01
    “…[xl]  Pierson et al., supra. [xli]  Food and Drug Administration, supra. [xlii]  Hurst, supra. …”
    Get full text
    Article
  14. 234

    Approved antibacterial drugs in the last 10 years: from the bench to the clinic by Miguel García-Castro, Francisco Sarabia, Amelia Díaz-Morilla, Juan Manuel López-Romero

    Published 2023-06-01
    “…This article covers the most recent antibacterial molecules approved by the Food and Drugs Administration (FDA) and European Medicines Agency (EMA) from 2012 to 2022 and intends to focus on synthetic derivatives to give a pedagogical view, with the goal of highlighting the importance of organic synthesis to obtain greater efficacy. …”
    Get full text
    Article
  15. 235

    Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review by Kiran Shah, Nirali Shah, Fatameh Ghassemi, Carolyn Ly, Teena George, Carla Lutz, Huseyin Sumer

    Published 2022-01-01
    “…The area has been further strengthened with the approval of Chimeric Antigen Receptor added on T cells (CAR-T) therapies by the regulatory authorities USA’s Food and Drugs Administration (FDA), European Medical Agency (EMA), the Australian Therapeutic Goods Administration (TGA), and in many countries in 2017 to treat hematological cancers. …”
    Get full text
    Article